Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRUG Bright Minds Biosciences Inc

Market Closed 12-12 16:00:00 EST

84.19

-4.82

-5.42%

盘后84.19

+0.000.00%

19:45 EST

High93.40	Low81.91	Vol84.17K
Open89.21	D1 Closing89.01	Amplitude12.91%
Mkt Cap596.79M	Tradable Cap252.90M	Total Shares7.09M
T/O7.17M	T/O Rate2.80%	Tradable Shares3.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DRUG","market":"US","secType":"STK","nameCN":"Bright Minds Biosciences Inc","latestPrice":84.19,"timestamp":1765573200000,"preClose":89.01,"halted":0,"volume":84173,"hourTrading":{"tag":"盘后","latestPrice":84.19,"preClose":84.19,"latestTime":"19:45 EST","volume":94,"amount":7915.84,"timestamp":1765586712701},"delay":0,"floatShares":3003920,"shares":7088639,"eps":-1.05653,"marketStatus":"Market Closed","change":-4.82,"latestTime":"12-12 16:00:00 EST","open":89.21,"high":93.4,"low":81.9105,"amount":7168183.62249,"amplitude":0.129081,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.05653,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":89.01,"preHourTrading":{"tag":"盘前","latestPrice":89.03,"preClose":89.01,"latestTime":"09:25 EST","volume":25,"amount":2239.98985,"timestamp":1765549500009},"postHourTrading":{"tag":"盘后","latestPrice":84.19,"preClose":84.19,"latestTime":"19:45 EST","volume":94,"amount":7915.84,"timestamp":1765586712701},"volumeRatio":0.633354751874903},"requestUrl":"/m/hq/s/DRUG/wiki","defaultTab":"wiki","newsList":[{"id":"2584405726","title":"Press Release: Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584405726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584405726?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:50","pubTimestamp":1763380200,"startTime":"0","endTime":"0","summary":"-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which was announced on November 6, 2025 --. NEW YORK and VANCOUVER, British Columbia, Nov. 17, 2025  -- Bright Minds Biosciences Inc.    today announced the addition of four global experts in Prader-Willi Syndrome  to its Scientific Advisory Board :. On November 6, 2025, the Company held a KOL event to announce the initiation of its PWS program and the nomination of BMB-105 as a new clinical candidate. A replay of the presentation is available in the Investor section of the Company's website under News & Events.Dr. Jennifer Miller is a Professor in the division","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2211817866.USD","FPWR","IE00BYQQ9H92.USD","BK4121","BK4548","LU2413666699.HKD","LU0347712357.USD","LU1721428933.USD","PWS","DRUG","BK4533","LU1093756325.SGD","LU2413666426.HKD","MTD","BK4588","IE00BFXG0V08.USD","BK4567","LU1093756168.USD","BK4585"],"gpt_icon":0},{"id":"2579101854","title":"Bright Minds Biosciences to Present at Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2579101854","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579101854?lang=en_us&edition=fundamental","pubTime":"2025-10-31 06:30","pubTimestamp":1761863400,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct.  30, 2025  (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3178037/0/en/Bright-Minds-Biosciences-to-Present-at-Upcoming-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","CNS","DRUG"],"gpt_icon":0},{"id":"2565882696","title":"Bright Minds Biosciences Inc : Btig Initiates Coverage With Buy Rating; Target Price $72","url":"https://stock-news.laohu8.com/highlight/detail?id=2565882696","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565882696?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:40","pubTimestamp":1757328049,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nFWN3UV0W6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DRUG","BK4139"],"gpt_icon":0},{"id":"2565851555","title":"Bright Minds Biosciences Enters Deal for $100 Million At-The-Market Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2565851555","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565851555?lang=en_us&edition=fundamental","pubTime":"2025-09-05 16:46","pubTimestamp":1757062009,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences  said late Thursday it has entered an agreement with Piper Sandler and Cantor Fitzgerald to establish an at-the-market equity offering of up to $100 million.The program will run for three years, the company said.Bright Minds intends to use any funds raised for general corporate purposes, it said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","DRUG","DRUG.AU"],"gpt_icon":0},{"id":"2564090374","title":"Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2564090374","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564090374?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:30","pubTimestamp":1756989000,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  04, 2025  (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB201, in a validated isoso","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/04/3144527/0/en/Bright-Minds-Biosciences-Announces-BMB-201-Outperforms-Sumatriptan-in-Validated-Preclinical-Vascular-Headache-Model.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRUG","BK4139"],"gpt_icon":0},{"id":"2562724971","title":"Bright Minds Biosciences to Present at Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2562724971","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562724971?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:00","pubTimestamp":1756123200,"startTime":"0","endTime":"0","summary":"NEW YORK, Aug.  25, 2025  (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/25/3138410/0/en/Bright-Minds-Biosciences-to-Present-at-Upcoming-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRUG","BK4139","BK4135","CNS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.brightmindsbio.com","stockEarnings":[{"period":"1week","weight":0.0458},{"period":"1month","weight":0.3997},{"period":"3month","weight":0.727},{"period":"6month","weight":2.0526},{"period":"1year","weight":1.1314},{"period":"ytd","weight":1.3373}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.048249},{"month":2,"riseRate":0.25,"avgChangeRate":-0.102538},{"month":3,"riseRate":0,"avgChangeRate":-0.218801},{"month":4,"riseRate":0.25,"avgChangeRate":-0.074949},{"month":5,"riseRate":0.5,"avgChangeRate":0.068312},{"month":6,"riseRate":0.25,"avgChangeRate":-0.114262},{"month":7,"riseRate":1,"avgChangeRate":0.265332},{"month":8,"riseRate":0.5,"avgChangeRate":0.127885},{"month":9,"riseRate":0.5,"avgChangeRate":0.012143},{"month":10,"riseRate":0.25,"avgChangeRate":9.6378},{"month":11,"riseRate":0.5,"avgChangeRate":0.078078},{"month":12,"riseRate":0.4,"avgChangeRate":-0.094479}],"exchange":"NASDAQ","name":"Bright Minds Biosciences Inc","nameEN":"Bright Minds Biosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Bright Minds Biosciences Inc(DRUG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Bright Minds Biosciences Inc,DRUG,Bright Minds Biosciences Inc股票,Bright Minds Biosciences Inc股票老虎,Bright Minds Biosciences Inc股票老虎国际,Bright Minds Biosciences Inc行情,Bright Minds Biosciences Inc股票行情,Bright Minds Biosciences Inc股价,Bright Minds Biosciences Inc股市,Bright Minds Biosciences Inc股票价格,Bright Minds Biosciences Inc股票交易,Bright Minds Biosciences Inc股票购买,Bright Minds Biosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Bright Minds Biosciences Inc(DRUG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction